Literature DB >> 1975508

Towards a more rapid diagnosis of rapidly progressive glomerulonephritis.

M J Cassidy1, G Gaskin, J Savill, C D Pusey, A J Rees.   

Abstract

An attempt was made to provide simple practical guidelines to alert general practitioners to the diagnosis of rapidly progressive glomerulonephritis and lead to early referral to hospital. The duration of illness before referral to this hospital and its effect on outcome in patients with crescentic nephritis were assessed retrospectively from the case notes of 24 patients referred over two years. Four patients had Goodpasture's syndrome, 11 Wegener's granulomatosis, seven microscopic polyarteritis, and two idiopathic progressive glomerulonephritis. The duration of symptoms before referral to the local hospital was similar in the four groups of patients and varied from one week to 28 months (mean 10 months). The duration of stay in the local hospital was two, nine, 11, and 180 days in the patients with Goodpasture's syndrome and a mean of four days (range one to eight) in those with Wegener's granulomatosis and 10 days (one to 18 days) in those with microscopic polyarteritis. In the local hospital the diagnosis was based on the results of renal biopsy and detection of antibodies to glomerular basement membrane in two patients with Goodpasture's syndrome and on the results of renal biopsy in seven of the other patients aided by the detection of antibodies to the cytoplasm of neutrophils (ANCA) in 10. Three of the 24 patients died and four required maintenance haemodialysis. Patients who present to their general practitioners with persistent non-specific symptoms should have a urine dipstick test and then blood tests and emergency referral to hospital if necessary. Hospital physicians should be aware of the speed and accuracy with which current assays can confirm a diagnosis of rapidly progressive glomerulonephritis.

Entities:  

Mesh:

Year:  1990        PMID: 1975508      PMCID: PMC1663619          DOI: 10.1136/bmj.301.6747.329

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  5 in total

Review 1.  The current status of neutrophil cytoplasmic antibodies.

Authors:  F J van der Woude; M R Daha; L A van Es
Journal:  Clin Exp Immunol       Date:  1989-11       Impact factor: 4.330

Review 2.  Autoimmunity in rapidly progressive glomerulonephritis.

Authors:  C D Pusey; C M Lockwood
Journal:  Kidney Int       Date:  1989-04       Impact factor: 10.612

3.  Prognosis after immunosuppression of patients with crescentic nephritis requiring dialysis.

Authors:  C R Hind; H Paraskevakou; C M Lockwood; D J Evans; D K Peters; A J Rees
Journal:  Lancet       Date:  1983-02-05       Impact factor: 79.321

4.  Wegener's granulomatosis: observations on 18 patients with severe renal disease.

Authors:  A J Pinching; C M Lockwood; B A Pussell; A J Rees; P Sweny; D J Evans; N Bowley; D K Peters
Journal:  Q J Med       Date:  1983

5.  Microscopic polyarteritis: presentation, pathology and prognosis.

Authors:  C O Savage; C G Winearls; D J Evans; A J Rees; C M Lockwood
Journal:  Q J Med       Date:  1985-08
  5 in total
  5 in total

1.  Long-term clinical course in acute crescentic glomerulonephritis.

Authors:  D Bach; K Hauser; B Grabensee
Journal:  Int Urol Nephrol       Date:  1996       Impact factor: 2.370

2.  The haematuria clinic.

Authors:  P Marazzi; R Gabriel
Journal:  BMJ       Date:  1994-02-05

3.  Rapidly progressive glomerulonephritis in two Zambian children: a case report.

Authors:  Chisambo Mwaba; Chibamba Ngomalala Mumba; Musyani Simukonde; Somwe Wa Somwe
Journal:  Pan Afr Med J       Date:  2022-05-10

Review 4.  [Rapidly progressive glomerulonephritis:classification, pathogenesis and clinical management].

Authors:  R Birck; F J Van Der Woude
Journal:  Internist (Berl)       Date:  2003-09       Impact factor: 0.743

5.  Crescents in Kidney Biopsy - What Do They Imply? A Clinicopathologic Study of 40 Cases in a Tertiary Care Center.

Authors:  Shivangi Chauhan; Sonal Jain; Neha Garg; Sonali Dixit; Sonal Sharma
Journal:  J Microsc Ultrastruct       Date:  2021-05-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.